Assessment of antibody titers and immunity to Hepatitis B in children receiving chemotherapy
Authors
Abstract:
Abstract Background There is a decrease in vaccine-specific antibody to certain vaccine-preventable diseases in children after chemotherapy, but the frequency of non-immune patients is not clear. In the present case-control study, was taken under investigation protection level to Hepatitis B infection in children 6 months after completing chemotherapy. Materials and Methods In this study 68 patients with cancer and 68 healthy children were enrolled. Patients were 1.5 -12 years old with completed standard chemotherapy at least for 6 months. All the patients and healthy children were negative for HBsAg and HBeAg and had received Hepatitis B vaccination. IgG antibody concentrations against Hepatitis B Virus (HBV) were determined in the patients receiving chemotrapy and healthy subjects serum by ELISA method. IgG antibody titer > 10 mIU/ml was considered as baseline protective titer for preventing HBV infection. Results Anti-HBs antibody titer in 19.12% of patients was less than 10 mIU/ml and 11.76% of the patients had borderline antibody titer (10-20 mIU/ml). In healthy subjects, 2.94% and 5.88% had antibody titer < 10 mIU/ml and 10-20 mIU/ml, respectively. According to statistical analysis, frequency of non immune subjects in children with cancer was significantly higher than those in healthy children (P-value=0.024). Conclusion HBV vaccination post-intensive chemotherapy in the children with cancer is strongly recommended.
similar resources
Immunity in Leprosy, in Relation to Antibody Titers of Epstein-Barr Virus Capsid Antigen
This article has no abstract.
full textDetermination of Hepatitis B Surface Antibody Titer in Vaccinated Children with Major Thalassemia in Kerman-Iran
Background: Thalassemia patients are more susceptible to hepatitis than the normal population due to the frequent blood transfusions. Objective: To determine the immune response of children with major ß-thalassemia, by measuring anti-hepatitis B surface antibody (anti-HBs Ab) following the last HBV vaccine injection. Methods: This study was carried out on 215 thalassemic children who received t...
full textOccult Hepatitis B in Patients Undergoing Chemotherapy
Introduction: The hepatitis B virus (HBV) is one health problem in Iran. Occult hepatitis B (OBI) is diagnosed by the detection of HBV DNA in the serum or liver tissue of patients for whom other serology, especially HBsAg and HBcAg, are negative. The current study aimed to determine the prevalence of OBI in patients who refer for chemotherapy. Methods: Al...
full textcan Isolated hepatitis B core antibody in HIV-infected patients response to hepatitis B vaccine help to elucidate the cause?
full text
Reactivation of hepatitis B virus in patients receiving chemotherapy.
In patients undergoing chemotherapy for the treatment of malignant disease, the reactivation of hepatitis B virus in hepatitis B surface antigen-positive patients has been frequently reported. However, activation has also been reported in hepatitis B surface antigen-negative patients who test positive for hepatitis B core antibody and/or hepatitis B surface antibody, who were thought to have ha...
full textMy Resources
Journal title
volume 2 issue 4
pages 133- 139
publication date 2012-12
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023